武汉新型冠状病毒应对方略之十五--我写的武汉病毒DNA疫苗应对方略已经成为美国疾病防控中心的实际行动
今天看新闻，发现我这两天在知乎上写的武汉新型冠状病毒应对方略已经成为美国疾病防控中心的实际行动， 非常感慨。前情提要，武汉新型冠状病毒危机的爆发，我认为快速的解决策略就是尽快开发DNA疫苗。
为了催化这个过程，我甚至还专门写文章介绍具体步骤细节。
今天看到新闻，美国国立健康研究院NIH和疾病防控中心CDC已经提供九百万美元的研究经费让两家公司开发针对武汉病毒的DNA疫苗，其中一家公司就是MERS冠状病毒DNA疫苗的生产商Inovio。
Inovio's participation in this developing effort is based on the ideal suitability of its DNA medicine platform to rapidly develop a vaccine against an emerging virus with pandemic potential, proven vaccine development capabilities and a strong track record of rapidly generating promising countermeasures against previous pandemic threats. Inovio was the first to advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into evaluation in humans. Inovio is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred.
DNA疫苗的优点就是快速生产出针对新型病毒的疫苗，传统疫苗需要超过一年，而DNA疫苗快的话只要2-3个月。
In a recently published paper in Lancet Infectious Diseases, Inovio's Phase 1 study of its MERS-CoV vaccine demonstrated it was well tolerated and furthermore induced high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.
Inovio的MERS冠状病毒疫苗可以让95%的接种者产生抗体，T细胞免疫反应接近90%， 维持时间超过60周。
我很希望中国卫生部和卫计委能够有美国国立健康研究院NIH和疾病防控中心CDC这样的行动效率，迅速决策生产针对新型冠状病毒的DNA疫苗并尽快开展人体临床实验。
页:
[1]